OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) in Previously-Treated Malignant Mesothelioma (MM): Final Analysis
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.277
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV